CalciMedica posts Q1 profit on higher other income, lower expenses

Calcimedica

12/05/2026 12:16

Overview

Biopharmaceutical firm's Q1 net income rose to $5.0 mln, reversing a year-ago loss

Operating expenses fell due to lower R&D and personnel costs

Net income increase driven by fair value adjustments to financial instruments

Outlook

Company expects FDA feedback on Auxora pivotal program in AP in 2Q 2026

Result Drivers

LOWER R&D AND CLINICAL COSTS - Co said research and development expenses fell due to decreased preclinical and clinical trial activities and lower chemistry, manufacturing, and controls costs

LOWER PERSONNEL COSTS - General and administrative expenses declined, mainly due to reduced personnel costs

FAIR VALUE ADJUSTMENTS - Net income increase was mainly driven by fair value adjustments to promissory note and common stock warrants

Company press release: ID:nPn881t9Pa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
$4.98 mln
Q1 Income From Operations
-$5.61 mln
Q1 Operating Expenses
$5.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CalciMedica Inc is $10.00, about 1,592% above its May 11 closing price of $0.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)